105686-91-7

Basic information

• Product Name: 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE
• Synonyms: 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE
• CAS NO: 105686-91-7
• Molecular Formula: C₁₉H₂₀O₅
• Molecular Weight: 328.36
• Mol File: 105686-91-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE(105686-91-7)
• EPA Substance Registry System: 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE(105686-91-7)

Safety Data

• Hazardous Substances Data: 105686-91-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE is used as a starting material for the development of new drugs or biologically active compounds due to its potential medicinal or biological activity.
Used in Medicinal Research:
In the field of medicinal research, 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE is used as a compound with antioxidant and anti-inflammatory properties, which can be further explored for the treatment of various diseases and conditions.
Used in Antioxidant Applications:
Given its antioxidant properties, 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE can be used as an additive in the food and cosmetic industries to extend shelf life and provide skin protection, respectively.
Used in Anti-Inflammatory Applications:
The anti-inflammatory properties of 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE make it a potential candidate for the development of anti-inflammatory drugs, which could be used in the treatment of conditions such as arthritis and other inflammatory diseases.
Used in the Development of Nutraceuticals:
Due to its potential health benefits, 1-(4-METHOXYPHENYL)-3-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE may be utilized in the development of nutraceuticals, which are substances that provide medical or health benefits, including the prevention and treatment of diseases.

Upstream product

• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 1136-86-3 methyl (3,4,5-trimethoxyphenyl) ketone 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 182363-47-9 4-(4-Methoxy-phenyl)-6-(3,4,5-trimethoxy-phenyl)-5,6-dihydro-1H-pyrimidine-2-thione 
• 169804-56-2 4-(4-Methoxy-phenyl)-4-oxo-2-(3,4,5-trimethoxy-phenyl)-butyronitrile 
• 851729-13-0 1-(4-methoxyphenyl)(3-(3,4,5-trimethoxyphenyl)oxiran-2-yl)methanone 
• 56177-96-9 3-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)propane 
• 110047-50-2 1-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)propan-1-one 

Relevant articles and documents

Synthesis and antimitotic properties of ortho-substituted polymethoxydiarylazolopyrimidines

Ortho-substituted polymethoxydiarylazolopyrimidines were synthesized using polymethoxysubstituted benzaldehydes and acetophenones as starting material. X-ray crystallography data clearly confirmed that the subsequent cyclization of 3-amino-1,2,4-triazole

[a]-Phenanthrene-fused BF2 azadipyrromethene (AzaBODIPY) dyes as bright near-infrared fluorophores

A new substitution pattern of BF2 azadipyrromethene (azaBODIPY) dyes was obtained by phenanthrene fusion through a key palladium-catalyzed intramolecular C-H activation reaction. These [a]-phenanthrene-fused azaBODIPYs have a near planar struct

The influence of methoxy and ethoxy groups on supramolecular arrangement of two methoxy-chalcones

The structures of two methoxylated chalcones, namely (E)-1-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one and (E)-3-(4-ethoxyphenyl)-1-(4-methoxyphenyl) prop-2-en-1-one, reveal the effect of the inclusion of the methoxyl and ethoxyl substitue

Design, synthesis, biological evaluation of 3,5-diaryl-4,5-dihydro-1H-pyrazole carbaldehydes as non-purine xanthine oxidase inhibitors: Tracing the anticancer mechanism via xanthine oxidase inhibition

Xanthine oxidase (XO) has been primarily targeted for the development of anti-hyperuriciemic /anti-gout agents as it catalyzes the conversion of xanthine and hypoxanthine into uric acid. XO overexpression in various cancer is very well correlated due to r

A novel series of benzothiazepine derivatives as tubulin polymerization inhibitors with anti-tumor potency

In this work, a series of diaryl benzo[b][1,4]thiazepine derivatives D1-D36 were synthesized and screened as tubulin polymerization inhibitors with anti-tumor potency. They were designed by introducing the seven-member ring benzothiazepine as the linker f

Chalcones bearing a 3,4,5-trimethoxyphenyl motif are capable of selectively inhibiting oncogenic K-Ras signaling

Ras proteins are small GTPases which regulate cellular proliferation, differentiation, and apoptosis. Constitutively active mutant Ras are expressed in ~15–20% human cancers, and K-Ras mutations account for ~85% of all Ras mutations. Despite the significa

The synthesis of chalcones as anticancer prodrugs and their bioactivation in CYP1 expressing breast cancer cells

Background: Although the expression levels of many P450s differ between tumour and corresponding normal tissue, CYP1B1 is one of the few CYP subfamilies which is significantly and consistently overexpressed in tumours. CYP1B1 has been shown to be active within tumours and is capable of metabolising a structurally diverse range of anticancer drugs. Because of this, and its role in the activation of procarcinogens, CYP1B1 is seen as an important target for anticancer drug development. Objective: To synthesise a series of chalcone derivatives based on the chemopreventative agent DMU-135 and investigate their antiproliferative activities in human breast cancer cell lines which express CYP1B1 and CYP1A1. Method: A series of chalcones were synthesised in yields of 43-94% using the Claisen-Schmidt condensation reaction. These were screened using a MTT assay against a panel of breast cancer cell lines which have been characterised for CYP1 expression. Result: A number of derivatives showed promising antiproliferative activities in human breast cancer cell lines which express CYP1B1 and CYP1A1, while showing significantly lower toxicity towards a non-tumour breast cell line with no CYP expression. Experiments using the CYP1 inhibitors acacetin and α-naphthoflavone provided supporting evidence for the involvement of CYP1 enzymes in the bioactivation of these compounds. Conclusion: Chalcones show promise as anticancer agents with evidence suggesting that CYP1 activation of these compounds may be involved.

Synthesis and antimitotic properties of ortho-substituted polymethoxydiarylazolopyrimidines

Ortho-substituted polymethoxydiarylazolopyrimidines were synthesized using polymethoxysubstituted benzaldehydes and acetophenones as starting material. X-ray crystallography data clearly confirmed that the subsequent cyclization of 3-amino-1,2,4-triazole

Azine-Hydrazone Tautomerism of Guanylhydrazones: Evidence for the Preference Toward the Azine Tautomer

Guanylhydrazones have been known for a long time and have wide applications in organic synthesis, medicinal chemistry, and material science; however, little attention has been paid toward their electronic and structural properties. Quantum chemical analysis on several therapeutically important guanylhydrazones indicated that all of them prefer the azine tautomeric state (by about 3-12 kcal/mol). A set of simple and conjugated azines were designed using quantum chemical methods, whose tautomeric preference toward the azine tautomer is in the range of 3-8 kcal/mol. Twenty new azines were synthesized and isolated in their neutral state. Variable temperature NMR study suggests existence of the azine tautomer even at higher temperatures with no traces of the hydrazone tautomer. The crystal structures of two representative compounds confirmed that the title compounds prefer to exist in their azine tautomeric form.

Microwave-Assisted condensation reactions of acetophenone derivatives and activated methylene compounds with aldehydes catalyzed by boric acid under solvent-free conditions

We here disclosed a new protocol for the condensation of acetophenone derivatives and active methylene compounds with aldehydes in the presence of boric acid under microwave conditions. Implementation of the reaction is simple, healthy and environmentally